Quarterly report · Q1

Period2024-01-01 → 2024-03-31
Filed2024-04-30
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥519.5bn2024-01-01 → 2024-03-31Cons.Revenue IFRS
Revenue¥2.02T2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥448.3bn2023-01-01 → 2023-03-31Cons.Revenue IFRS
Operating income¥92.0bn2024-01-01 → 2024-03-31Cons.Operating profit loss IFRS
Operating income¥76.8bn2023-01-01 → 2023-03-31Cons.Operating profit loss IFRS
Profit before tax¥100.1bn2024-01-01 → 2024-03-31Cons.Profit loss before tax IFRS
Profit before tax¥142.7bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥79.2bn2023-01-01 → 2023-03-31Cons.Profit loss before tax IFRS
Net income (owners)¥77.4bn2024-01-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥121.6bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥61.4bn2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS
Net income¥78.9bn2024-01-01 → 2024-03-31Cons.Profit loss IFRS
Net income¥62.7bn2023-01-01 → 2023-03-31Cons.Profit loss IFRS
Total assets¥3.45Tat 2024-03-31Cons.Assets IFRS
Total assets¥3.36Tat 2023-12-31Cons.Assets IFRS
Total assets¥3.13Tat 2023-03-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥894.5bnat 2024-03-31Cons.Liabilities IFRS
Total liabilities¥924.9bnat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥2.56Tat 2024-03-31Cons.Equity IFRS
Net assets / equity¥2.44Tat 2023-12-31Cons.Equity IFRS
Net assets / equity¥2.32Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥2.26Tat 2022-12-31dCons.Equity IFRS
Equity (owners)¥2.51Tat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.39Tat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥2.28Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥411.6bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥513.3bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥477.1bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥471.6bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥36.4bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥283.2bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥71.9bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥91.5bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥190.5bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥35.8bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥58.7bn2024-01-01 → 2024-03-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥60.3bn2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥32.7bn2023-01-01 → 2023-03-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥142.592024-01-01 → 2024-03-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥224.12023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥113.22023-01-01 → 2023-03-31Cons.Basic earnings loss per share IFRS
EPS (diluted)¥142.592024-01-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥224.12023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥113.182023-01-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS
Equity ratio72.8%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio71.2%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio72.8%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-01-01 → 2024-03-31¥27.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-01-01 → 2024-03-31¥26.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-01-01 → 2024-03-31¥872m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-01-01 → 2024-03-31¥1.9bn
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-03-31−¥881m
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-03-31−¥881m
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-03-31−¥10.8bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue2024-01-01 → 2024-03-31¥7.3bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue external2024-01-01 → 2024-03-31¥7.3bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥1m
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentsegment profit2024-01-01 → 2024-03-31¥4.3bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue2024-01-01 → 2024-03-31¥126.2bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue external2024-01-01 → 2024-03-31¥126.2bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2024-01-01 → 2024-03-31¥6m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentsegment profit2024-01-01 → 2024-03-31¥16.8bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue2024-01-01 → 2024-03-31¥359.6bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue external2024-01-01 → 2024-03-31¥359.6bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentsegment profit2024-01-01 → 2024-03-31¥79.8bn
—segment totalrevenue2024-01-01 → 2024-03-31¥520.4bn
—segment totalrevenue external2024-01-01 → 2024-03-31¥519.5bn
—segment totalrevenue intersegment2024-01-01 → 2024-03-31¥881m
—segment totalsegment profit2024-01-01 → 2024-03-31¥102.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-01-01 → 2023-03-31¥27.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-01-01 → 2023-03-31¥26.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-01-01 → 2023-03-31¥723m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-01-01 → 2023-03-31¥3.1bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-03-31−¥742m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-03-31−¥742m
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-03-31−¥12.9bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue2023-01-01 → 2023-03-31¥8.2bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue external2023-01-01 → 2023-03-31¥8.2bn
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥4m
jpcrp040300-q1r_E21183-000Consumer Productsreportable segmentsegment profit2023-01-01 → 2023-03-31¥2.2bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue2023-01-01 → 2023-03-31¥104.0bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue external2023-01-01 → 2023-03-31¥104.0bn
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentrevenue intersegment2023-01-01 → 2023-03-31¥13m
jpcrp040300-q1r_E21183-000Nutraceuticalsreportable segmentsegment profit2023-01-01 → 2023-03-31¥10.8bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue2023-01-01 → 2023-03-31¥309.5bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentrevenue external2023-01-01 → 2023-03-31¥309.5bn
jpcrp040300-q1r_E21183-000Pharmaceuticalsreportable segmentsegment profit2023-01-01 → 2023-03-31¥73.6bn
—segment totalrevenue2023-01-01 → 2023-03-31¥449.1bn
—segment totalrevenue external2023-01-01 → 2023-03-31¥448.3bn
—segment totalrevenue intersegment2023-01-01 → 2023-03-31¥742m
—segment totalsegment profit2023-01-01 → 2023-03-31¥89.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 694
ItemContextValueUnit
Independent auditors report consolidated (text)FilingDateInstantText · Plus
Audit firm1 consolidatedFilingDateInstant
Original text (Japanese)有限責任 あずさ監査法人
Cpa1 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)川 瀬 洋 人
Cpa2 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)鈴 木 専 行
Cpa3 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)松 尾 洋 孝
Number of submissionFilingDateInstant1
Revenue IFRS (5-year summary)Prior1YTDDuration448344000000JPY
Revenue IFRS (5-year summary)CurrentYTDDuration519517000000JPY
Revenue IFRS (5-year summary)Prior1YearDuration2018568000000JPY
Profit loss before tax IFRS (5-year summary)Prior1YTDDuration79242000000JPY
Profit loss before tax IFRS (5-year summary)CurrentYTDDuration100079000000JPY
Profit loss before tax IFRS (5-year summary)Prior1YearDuration142655000000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)Prior1YTDDuration61430000000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)CurrentYTDDuration77377000000JPY
Profit loss attributable to owners of parent IFRS (5-year summary)Prior1YearDuration121616000000JPY
Comprehensive income attributable to owners of parent IFRS (5-year summary)Prior1YTDDuration83148000000JPY
Comprehensive income attributable to owners of parent IFRS (5-year summary)CurrentYTDDuration150469000000JPY
Comprehensive income attributable to owners of parent IFRS (5-year summary)Prior1YearDuration222855000000JPY
Equity attributable to owners of parent IFRS (5-year summary)Prior1QuarterInstant2281415000000JPY
Equity attributable to owners of parent IFRS (5-year summary)CurrentQuarterInstant2511586000000JPY
Equity attributable to owners of parent IFRS (5-year summary)Prior1YearInstant2393683000000JPY
Total assets IFRS (5-year summary)Prior1QuarterInstant3132041000000JPY
Total assets IFRS (5-year summary)CurrentQuarterInstant3449786000000JPY
Total assets IFRS (5-year summary)Prior1YearInstant3361244000000JPY
Basic earnings loss per share IFRS (5-year summary)Prior1YTDDuration113.20
Basic earnings loss per share IFRS (5-year summary)CurrentYTDDuration142.59
Basic earnings loss per share IFRS (5-year summary)Prior1YearDuration224.10
Diluted earnings loss per share IFRS (5-year summary)Prior1YTDDuration113.18
Diluted earnings loss per share IFRS (5-year summary)CurrentYTDDuration142.59
Diluted earnings loss per share IFRS (5-year summary)Prior1YearDuration224.10
Ratio of owners equity to gross assets IFRS (5-year summary)Prior1QuarterInstant0.728
Ratio of owners equity to gross assets IFRS (5-year summary)CurrentQuarterInstant0.728
Ratio of owners equity to gross assets IFRS (5-year summary)Prior1YearInstant0.712
Cash flows from used in operating activities IFRS (5-year summary)Prior1YTDDuration71882000000JPY
Cash flows from used in operating activities IFRS (5-year summary)CurrentYTDDuration36420000000JPY
Cash flows from used in operating activities IFRS (5-year summary)Prior1YearDuration283232000000JPY
Cash flows from used in investing activities IFRS (5-year summary)Prior1YTDDuration-35771000000JPY
Cash flows from used in investing activities IFRS (5-year summary)CurrentYTDDuration-91459000000JPY
Cash flows from used in investing activities IFRS (5-year summary)Prior1YearDuration-190538000000JPY
Cash flows from used in financing activities IFRS (5-year summary)Prior1YTDDuration-32659000000JPY
Cash flows from used in financing activities IFRS (5-year summary)CurrentYTDDuration-58697000000JPY
Cash flows from used in financing activities IFRS (5-year summary)Prior1YearDuration-60260000000JPY
Cash and cash equivalents IFRS (5-year summary)Prior1QuarterInstant477137000000JPY
Cash and cash equivalents IFRS (5-year summary)CurrentQuarterInstant411622000000JPY
Cash and cash equivalents IFRS (5-year summary)Prior1YearInstant513341000000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember557835617
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember557835617
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant557835617
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant557835617
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember-

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-03-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass